The cancer paradigms of mammalian regeneration: Can mammals regenerate as amphibians?

Carcinogenesis

Volumn 38, Issue 4, 2017, Pages 359-366

  Sarig, Rachel ^a   Tzahor, Eldad ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIBIA; CARCINOGENESIS; CELL DEDIFFERENTIATION; CELL POPULATION; EMBRYO CELL; EMBRYONIC STEM CELL; HUMAN; MALIGNANT NEOPLASM; MAMMAL; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; REGENERATION; REGULATORY MECHANISM; REVIEW; SOMATIC CELL; ANIMAL; CELL DIFFERENTIATION; CELL TRANSFORMATION; HEART; NEOPLASM; PATHOLOGY; PHYSIOLOGY; STEM CELL;

AMPHIBIANS; ANIMALS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; HEART; HUMANS; MAMMALS; NEOPLASMS; REGENERATION; STEM CELLS;

EID: 85019552135     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgw103     Document Type: Review

References (90)

1. Virchow, R. (1855) Editoral Archiv fuer pathologische Anatomie und Physiologie und fuer klinische Medizin. 8, 23
2. Sell, S. (2004) Stem cell origin of cancer and differentiation therapy. Crit. Rev. Oncol. Hematol., 51, 1-28
3. Ma, Y. et al. (2010) The relationship between early embryo development and tumourigenesis. J. Cell. Mol. Med., 14, 2697-2701
4. Ben-Porath, I. et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet., 40, 499-507
5. Reya, T. et al. (2001) Stem cells, cancer, and cancer stem cells. Nature, 414, 105-111
6. Wong, D.J. et al. (2008) Stemness, cancer and cancer stem cells. Cell Cycle, 7, 3622-3624
7. Lin, T. et al. (2005) p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat. Cell Biol., 7, 165-171
8. Tichy, E.D. (2011) Mechanisms maintaining genomic integrity in embryonic stem cells and induced pluripotent stem cells. Exp. Biol. Med. (Maywood)., 236, 987-996
9. Mintz, B. et al. (1975) Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl. Acad. Sci. USA, 72, 3585-3589
10. Illmensee, K. et al. (1976) Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc. Natl. Acad. Sci. USA, 73, 549-553
11. Kim, J. et al. (2015) Reprogramming of human cancer cells to pluripotency for models of cancer progression. EMBO J., 34, 739-747
12. Pomerantz, J.H. et al. (2013) Tumor suppressors: enhancers or suppressors of regeneration? Development, 140, 2502-2512
13. Pearson, B.J. et al. (2008) Regeneration, stem cells, and the evolution of tumor suppression. Cold Spring Harb. Symp. Quant. Biol., 73, 565-572
14. Molchadsky, A. et al. (2010) p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis, 31, 1501-1508
15. Muller, P.A. et al. (2014) Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell, 25, 304-317
16. Rivlin, N. et al. (2014) Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation. Proc. Natl. Acad. Sci. USA, 111, 7006-7011
17. Berger, A.H. et al. (2011) A continuum model for tumour suppression. Nature, 476, 163-169
18. Giachino, C. et al. (2013) Maintenance of genomic stability in mouse embryonic stem cells: relevance in aging and disease. Int. J. Mol. Sci., 14, 2617-2636
19. Shetzer, Y. et al. (2014) The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele. Cell Death Differ., 21, 1419-1431
20. Font-Burgada, J. et al. (2015) Hybrid periportal hepatocytes regenerate the injured liver without giving rise to cancer. Cell, 162, 766-779
21. Morrison, S.J. et al. (2006) Asymmetric and symmetric stem-cell divisions in development and cancer. Nature, 441, 1068-1074
22. Oviedo, N.J. et al. (2009) Regeneration: The origin of cancer or a possible cure? Semin. Cell Dev. Biol., 20, 557-564
23. Gurtner, G.C. et al. (2008) Wound repair and regeneration. Nature, 453, 314-321
24. Brockes, J.P. (1998) Regeneration and cancer. Biochim. Biophys. Acta, 1377, M1-11
25. Okamoto, M. (1997) Simultaneous demonstration of lens regeneration from dorsal iris and tumour production from ventral iris in the same newt eye after carcinogen administration. Differentiation, 61, 285-292
26. Quigley, D.A. et al. (2009) Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature, 458, 505-508
27. Best, J.B. et al. (1982) Planarians as a model system for in vitro teratogenesis studies. Teratog. Carcinog. Mutagen., 2, 277-291
28. Stoker, M. (1964) Regulation of growth and orientation in hamster cells transformed by polyoma virus. Virology, 24, 165-174
29. Allard, D. et al. (2003) A G2/M cell cycle block in transformed cells by contact with normal neighbors. Cell Cycle, 2, 484-487
30. Alkasalias, T. et al. (2014) Inhibition of tumor cell proliferation and motility by fibroblasts is both contact and soluble factor dependent. Proc. Natl. Acad. Sci. USA, 111, 17188-17193
31. Alexander, D.B. et al. (2004) Normal cells control the growth of neighboring transformed cells independent of gap junctional communication and SRC activity. Cancer Res., 64, 1347-1358
32. Flaberg, E. et al. (2011) High-throughput live-cell imaging reveals differential inhibition of tumor cell proliferation by human fibroblasts. Int. J. Cancer, 128, 2793-2802
33. Flaberg, E. et al. (2012) The architecture of fibroblast monolayers of different origin differentially influences tumor cell growth. Int. J. Cancer, 131, 2274-2283
34. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674
35. Raz, Y. et al. (2013) An inflammatory vicious cycle: Fibroblasts and immune cell recruitment in cancer. Exp. Cell Res., 319, 1596-1603
36. Takahashi, K. et al. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126, 663-676
37. Lamm, N. et al. (2016) Genomic instability in human pluripotent stem cells arises from replicative stress and chromosome condensation defects. Cell Stem Cell, 18, 253-261
38. Ben-David, U. et al. (2014) Aneuploidy induces profound changes in gene expression, proliferation and tumorigenicity of human pluripotent stem cells. Nat. Commun., 5, 4825
39. Mayshar, Y. et al. (2010) Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell, 7, 521-531
40. Sarig, R. et al. (2011) Can an iPS cell secure its genomic fidelity? Cell Death Differ., 18, 743-744
41. Tapia, N. et al. (2010) p53 connects tumorigenesis and reprogramming to pluripotency. J. Exp. Med., 207, 2045-2048
42. Polo, J.M. et al. (2012) A molecular roadmap of reprogramming somatic cells into iPS cells. Cell, 151, 1617-1632
43. Li, H. et al. (2009) The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature, 460, 1136-1139
44. Utikal, J. et al. (2009) Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature, 460, 1145-1148
45. Brosh, R. et al. (2013) p53 counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition. Cell Death Differ., 20, 312-320
46. Hong, H. et al. (2009) Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature, 460, 1132-1135
47. Kawamura, T. et al. (2009) Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature, 460, 1140-1144
48. Marion, R.M. et al. (2009) A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature, 460, 1149-1153
49. Krizhanovsky, V. et al. (2009) Stem cells: The promises and perils of p53. Nature, 460, 1085-1086
50. Sarig, R. et al. (2010) Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J. Exp. Med., 460, 2127-2140
51. Holland, A.J. et al. (2009) Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat. Rev. Mol. Cell Biol., 10, 478-487
52. Foudah, D. et al. (2009) Monitoring the genomic stability of in vitro cultured rat bone-marrow-derived mesenchymal stem cells. Chromosome Res., 17, 1025-1039
53. Josse, C. et al. (2010) Systematic chromosomal aberrations found in murine bone marrow-derived mesenchymal stem cells. Stem Cells Dev., 19, 1167-1173
54. Li, L.B. et al. (2012) Trisomy correction in Down syndrome induced pluripotent stem cells. Cell Stem Cell, 11, 615-619
55. Hochedlinger, K. et al. (2004) Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev., 18, 1875-1885
56. Li, L. et al. (2003) Mouse embryos cloned from brain tumors. Cancer Res., 63, 2733-2736
57. Miyoshi, N. et al. (2010) Defined factors induce reprogramming of gastrointestinal cancer cells. Proc. Natl. Acad. Sci. USA, 107, 40-45
58. Suvà, M.L. et al. (2013) Epigenetic reprogramming in cancer. Science, 339, 1567-1570
59. Doi, A. et al. (2009) Differential methylation of tissue-and cancerspecific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet., 41, 1350-1353
60. Zhang, X. et al. (2013) Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene, 32, 2249-60, 2260.e1
61. Kim, J. et al. (2013) An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep., 3, 2088-2099
62. Keller, C. et al. (2004) Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev., 18, 2608-2613
63. Roy, N.S. et al. (2006) Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med., 12, 1259-1268
64. Amariglio, N. et al. (2009) Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med., 6, e1000029
65. Ohnishi, K. et al. (2014) Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell, 156, 663-677
66. Kikuchi, K. et al. (2010) Primary contribution to zebrafish heart regeneration by gata4(+) cardiomyocytes. Nature, 464, 601-605
67. Ausoni, S. et al. (2009) From fish to amphibians to mammals: in search of novel strategies to optimize cardiac regeneration. J. Cell Biol., 184, 357-364
68. Garbern, J.C. et al. (2013) Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell, 12, 689-698
69. Porrello, E.R. et al. (2011) Transient regenerative potential of the neonatal mouse heart. Science, 331, 1078-1080
70. Li, F. et al. (1996) Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. J. Mol. Cell. Cardiol., 28, 1737-1746
71. Soonpaa, M.H. et al. (1996) Cardiomyocyte DNA synthesis and binucleation during murine development. Am. J. Physiol., 271(5 Pt 2), H2183-H2189
72. Naqvi, N. et al. (2014) A proliferative burst during preadolescence establishes the final cardiomyocyte number. Cell, 157, 795-807
73. Yahalom-Ronen, Y. et al. (2015) Reduced matrix rigidity promotes neonatal cardiomyocyte dedifferentiation, proliferation and clonal expansion. Elife, 4. doi:10.7554/eLife.07455
74. Mahmoud, A.I. et al. (2013) Meis1 regulates postnatal cardiomyocyte cell cycle arrest. Nature, 497, 249-253
75. Puente, B.N. et al. (2014) The oxygen-rich postnatal environment induces cardiomyocyte cell-cycle arrest through DNA damage response. Cell, 157, 565-579
76. Aurora, A.B. et al. (2014) Macrophages are required for neonatal heart regeneration. J. Clin. Invest., 124, 1382-1392
77. Heallen, T. et al. (2013) Hippo signaling impedes adult heart regeneration. Development, 140, 4683-4690
78. Kubin, T. et al. (2011) Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling. Cell Stem Cell, 9, 420-432
79. Kühn, B. et al. (2007) Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat. Med., 13, 962-969
80. Engel, F.B. et al. (2006) FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc. Natl. Acad. Sci. USA, 103, 15546-15551
81. Bersell, K. et al. (2009) Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell, 138, 257-270
82. D'Uva, G. et al. (2015) ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat. Cell Biol., 17, 627-638
83. Pan, D. (2010) The hippo signaling pathway in development and cancer. Dev. Cell, 19, 491-505
84. Zhao, B. et al. (2011) The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat. Cell Biol., 13, 877-883
85. Overholtzer, M. et al. (2006) Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl. Acad. Sci. USA, 103, 12405-12410
86. Mitri, Z. et al. (2012) The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother. Res. Pract., 2012, 743193
87. Coleman, S.J. et al. (2014) The ins and outs of fibroblast growth factor receptor signalling. Clin. Sci. (Lond)., 127, 217-231
88. Rovida, E. et al. (2015) Mitogen-activated protein kinases and Hedgehog-GLI signaling in cancer: a crosstalk providing therapeutic opportunities? Semin. Cancer Biol., 35, 154-167
89. Argiropoulos, B. et al. (2007) Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesis. Genes Dev., 21, 2845-2849
90. Field, L.J. (1988) Atrial natriuretic factor-SV40 T antigen transgenes produce tumors and cardiac arrhythmias in mice. Science, 239, 1029-1033